PIRS: Pieris Company Value to Net Income

Corporate emblem and logo of Pieris Pharmaceuticals Inc (PIRS)

Pieris Pharmaceuticals (PIRS) generates revenue through partnerships to develop biological drugs for combating cancer and respiratory diseases. Management is currently forced to cut secondary projects to preserve capital and regain market confidence. Despite this, the brand is valued for its expertise in developing anti-kallikreins. This price chart featuring the -32.70 indicator clearly illustrates the current position of this player.

PIRS Pieris Pharma: Price to Earnings Ratio in the range 07/04/2022 - 11/14/2026

Comprehensive metric breakdowns and analytics for Pieris (PIRS)

- price and consensus price forecast:
Stock Price pieris.com|PIRS - Consensus Target
- market capitalization information:
Market Value Pieris Pharmaceuticals, Inc.|PIRS - Total Company Value
- balance sheet net asset value indicators:
Net Asset Value per Share Pieris Pharmaceuticals|PIRS - Company Net Assets|Market Cap to Book Value Multiple pieris.com|PIRS - Company Total Assets
- company liabilities and liquidity data:
All Debt to Shareholders' Equity Ratio Pieris Pharmaceuticals|PIRS - Long-Term Debt to Capital|Current Liabilities to Capital Pieris Pharma|PIRS - Company Debts|Debt to Net Assets Ratio Pieris Pharmaceuticals, Inc.|PIRS - Company Long-Term Debt|Current Liabilities Pieris Pharmaceuticals|Interim Coverage Ratio pieris.com
- business earnings and investment ratios data:
PIRS - Net Profit|Expected Net Profit Pieris Pharmaceuticals|PIRS - Price to Earnings Ratio|Future Price to Earnings Multiple Pieris Pharmaceuticals Inc|PIRS - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio Pieris Pharmaceuticals, Inc.|PIRS - Profit before payment of interest, taxes and amortization|Net earnings per share for the last four quarters Pieris Pharmaceuticals|PIRS - Net earnings per share for the last 12 months|Year-over-year earnings per one share growth for the last 12 months pieris.com|PIRS - Earnings per share growth in current year|Net earnings per share change forecast for next year Pieris Pharmaceuticals
- issuer revenue and sales details:
PIRS - Revenue and Sales Volume|Company Future Revenue pieris.com|PIRS - P/S Multiple|Forward P/S Multiple Pieris Pharmaceuticals, Inc.
Comprehensive company analysis:pieris.com - PIRS
Flagship merchandise of Pieris Pharmaceuticals, Inc.

Pieris Pharmaceuticals (PIRS) is operating in crisis management mode following the termination of strategic partnerships. Analyzing the issuer's P/E history reveals the market reaction to liquidity risks and cash flow gaps. The multiple correlates market capitalization with net income, measuring the cost of each unit of earnings. High values signal either inflated expectations or a critical collapse in profits. Investors utilize this indicator to assess the viability of management's new business strategy.

Analysis of competing companies

P/E Multiple haleon.com|Price to Earnings Ratio KVUE (Kenvue)|VRNA (Verona Pharma PLC) - Company Value to Net Income|Price to Earnings Ratio Jyong Biotech Corp MENS|Ligand Corp (LGND) - Market Cap to Earnings|AMRX: Price to Earnings Ratio|perrigo.com - Market Price to Net Income Ratio|ALVO: P/E Multiple|Liquidia Corp - Company Value to Net Income|GLPG (Galapagos Genomics) - P/E Multiple|Market Cap to Earnings ANI Pharmaceuticals Corp ANIP|Price to Earnings Ratio MannKind Corporation (MNKD)|AMPH (amphastar.com) - Company Value to Net Income|Price to Earnings Ratio Pacira BioSciences, Inc. PCRX|SPRY (ARS Pharmaceuticals Inc) - Market Cap to Net Income|Theravance - P/E Multiple|Business Payback Period Aquestive Corp AQST|SCPH: P/E Multiple|Market Cap to Earnings Tectonic Therapeutic (TECX)|Price to Earnings Ratio Tonix Pharmaceuticals Holding Corp.|SXTC: Company Value to Net Income|P/E Multiple EPRX|Business Payback Period BioHarvest Sciences Inc|Price to Earnings Ratio eXoZymes Inc EXOZ|Business Payback Period Oramed (ORMP)|ENTX: Price to Earnings Ratio|Company Value to Net Income HYFT (MindWalk Holdings, Inc.)|ABVC BioPharma Inc (ABVC) - Price to Earnings Ratio|Market Cap to Net Income CPIX (Cumberland Corp)|QNTM (Quantum BioPharma Ltd) - P/E Multiple|FGEN: Company Value to Net Income|P/E Multiple TELO|P/E Multiple ranitherapeutics.com (RANI)|Price to Earnings Ratio Synergy CHC SNYR|Company Value to Net Income RLYB|LEXX - Price to Earnings Ratio|pulmatrix.com (PULM) - Price to Earnings Ratio|PTHL: P/E Multiple|Aptorum Group (APM) - P/E Multiple|LYRA (Lyra Therapeutics, Inc) - P/E Multiple|Price to Earnings Ratio Impact BioMedical, Inc. (IBO)|P/E Multiple TNFA|YCBD - Market Cap to Earnings|PainReform - Price to Earnings Ratio|P/E Multiple Altamira Therapeutics Ltd CYTO|LIPO: Price to Earnings Ratio|OptiNose Corp - Market Price to Net Income Ratio|PROC: P/E Multiple|PTPI - Business Payback Period|QLI (Qilian International Holding) - P/E Multiple|Price to Earnings Ratio Acelyrin Inc. (SLRN)|P/E Multiple TFFP